Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: A case for prospective economic analysis in cooperative group trials

This publication has 13 references indexed in Scilit:

• Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia
  New England Journal of Medicine, 1997
• Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients.
  Journal of Clinical Oncology, 1997
• Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.
  Journal of Clinical Oncology, 1996
• Identifying Early Predictors of Mortality in Pediatric Patients With Acute Leukemia and Pneumonia
  Chest, 1996
• Childhood Leukemias
  New England Journal of Medicine, 1995
• Prophylactic administration of granulocyte colony‐stimulating factor (filgrastim) after conventional chemotherapy in children with cancer
  The International Journal of Cell Cloning, 1995
• Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy
  Annals of Oncology, 1994
• The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy
  European Journal Of Cancer, 1993
• Pediatric oncology group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded)
  Cancer, 1985
• Modified LSA2-L2 treatment in 53 children with E-rosette-positive T- cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study)
  Blood, 1982